Supplemental Data Set

Characteristics of the cohort underpinning this cross-sectional study
Methods
Part A: Metabolomics profiling and data preprocessing
Part B: Drug deconfounding analysis
Part C: Transcriptomics profiling and data preprocessing
Table S1. Diagnosis and pharmacological treatment of 19 HIV-positive individuals with cardiovascular disease
Table S2. Classification of metabolomic features as dysmetabolic, escalation, de-escalation and CVD
Table S3. Classification of transcriptome features as dysmetabolic, escalation, de-escalation and CVD
Table S4. Classification of metabolomic features as dysmetabolic, escalation, de-escalation and CVD as well as comparison based on the cardiometabolic disease spectrum
Table S5. Pathway enrichment analysis of metabolome markers in the cardiometabolic disease spectrum in people living with HIV
Fig. S1 Operational classification of metabolome features from the perspective of CVD pathology
Fig. S2 Methodology employed for the classification of transcriptome features in the cross-sectional study
Fig. S3 Transcriptome features associated with CVD and its dysmetabolic pre-morbidities
Fig. S4 Functional enrichment analysis of transcriptome markers